Faculty profile

Steven Chan

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Steven Chan

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
13 publications in the last five years, latest in 2026.
Principal investigator on 8 research grants (8 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Clonal Hematopoiesis Hematopoietic Stem Cells Mouse Models Tet2 Acute Myeloid Leukemia Mitochondria Mpl Signaling Pathways

Latest papers

Extramedullary AML: Clinical and Molecular Features.
Cancers · 2026
What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?
Clinical lymphoma, myeloma & leukemia · 2026
Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.
Current oncology (Toronto, Ont.) · 2026

All 20 publications

Latest funding

Using Intravital Imaging to Understand how Acute Myeloid Leukemia Remodels the Bone Marrow Microenvironment In Vivo and how this Impacts Therapeutic Response
CIHR · 2026 · Co-investigator
$1,124,550
GLP-1 Receptor Agonists as a Preventive Strategy for Clonal Hematopoiesis-Driven Hematologic Cancers
CIHR · 2025 · Nominated PI
Investigating the role of dysregulated mitochondrial respiration in the pathogenesis of DNMT3A R882 mutation-driven clonal hematopoiesis
CIHR · 2025 · Nominated PI
$780,301

All 9 grants and awards

20 publications.

Extramedullary AML: Clinical and Molecular Features.

Morgenstern Y, Andrews C, Atenafu EG, Chan S, Gupta V, Minden MD, Maze D, Schimmer A, Schuh A, Yee K, Sibai H

Cancers2026

DOI: 10.3390/cancers18091362 PMID: 42122157

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Rajendra A, Smith E, Atenafu EG, Bankar A, Chan S, Davidson M, Gupta V, Minden MD, Perusini MA, Richard-Carpentier G, Schimmer A, Schuh AC, Sibai H, Yee K, Maze D

Clinical lymphoma, myeloma & leukemia2026

DOI: 10.1016/j.clml.2025.10.016 PMID: 41238480

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Eng DZS, Khadadah F, Perusini MA, Al-Shaibani E, Atenafu EG, Bankar A, Davidson M, Richard-Carpentier G, Maze D, Yee K, Schimmer A, Gupta V, Chan S, Kim DDH, Schuh A, Minden M, Sibai H

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33020127 PMID: 41744891

Identifying Risk Factors and Outcome for CNS Involvement in AML.

Seki JT, Daher-Reyes GS, Atenafu EG, Sibai J, Bankar A, Young T, Chan S, Yee K, Gupta V, Minden MD, Maze D, Schuh A, Schimmer A, Sibai H

Clinical lymphoma, myeloma & leukemia2025

DOI: 10.1016/j.clml.2025.06.010 PMID: 40744760

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.

Rajendra A, Smith E, Perusini MA, Tang K, Atenafu EG, Bankar A, Chan S, Davidson MB, Gupta V, Maze D, Minden MD, Richard-Carpentier G, Schimmer AD, Schuh AC, Yee K, Sibai H

Blood cancer journal2025

DOI: 10.1038/s41408-025-01353-2 PMID: 40854875

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.

Smith E, Atenafu EG, Bankar A, Chan S, Davidson M, Gupta V, Minden MD, Richard-Carpentier G, Schimmer A, Schuh AC, Sibai H, Yee K, Maze D

European journal of haematology2024

DOI: 10.1111/ejh.14283 PMID: 39113600

Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.

Lucero J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, Stockley T, Gupta V, Bankar A, Chan S, Schuh AC, Minden M, Mattsson J, Kumar R, Sibai H, Tierens A, Kim DDH

Annals of hematology2024

DOI: 10.1007/s00277-024-05639-6 PMID: 38291275

Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.

Davidson MB, Kennedy JA, Capo-Chichi JM, Shi Y, Xu W, Cheung V, Arruda A, Bankar A, Richard-Carpentier G, Chan S, Maze D, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee K, Tierens A, Viswabandya A, Gupta V

Blood advances2024

DOI: 10.1182/bloodadvances.2023011735 PMID: 38170760

Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis.

Vasudevan Nampoothiri R, Tang K, Schuh A, Lam W, Maze D, Michelis FV, Chan S, Gupta V, Kim D, Kumar R, Lipton JH, Mattsson J, Minden M, Schimmer A, Sibai H, Viswabandya A, Yee K, Murphy T, Law AD

European journal of haematology2023

DOI: 10.1111/ejh.13940 PMID: 36732677

Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.

Chen R, Atenafu EG, Seki J, Liu X, Chan S, Gupta V, Maze D, Shuh AC, Minden MD, Yee K, Schimmer AD, Sibai H

British journal of haematology2023

DOI: 10.1111/bjh.18683 PMID: 36794878

Something wrong or missing on this profile? Suggest a correction

Steven Chan

Research

Latest papers

Latest funding

Extramedullary AML: Clinical and Molecular Features.

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Identifying Risk Factors and Outcome for CNS Involvement in AML.

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.

Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.

Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.

Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis.

Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.

Using Intravital Imaging to Understand how Acute Myeloid Leukemia Remodels the Bone Marrow Microenvironment In Vivo and how this Impacts Therapeutic Response

GLP-1 Receptor Agonists as a Preventive Strategy for Clonal Hematopoiesis-Driven Hematologic Cancers

Investigating the role of dysregulated mitochondrial respiration in the pathogenesis of DNMT3A R882 mutation-driven clonal hematopoiesis

Preclinical Development of CMD-0001048: A First-in-Class PINK1 Inhibitor Targeting Leukemia Stem Cells in Acute Myeloid Leukemia

Inhibiting Thrombopoietin Receptor (TPO-R) Signaling as a Novel Approach to Target TET2 Mutation-Driven Clonal Hematopoiesis

Inhibiting Thrombopoietin Receptor (TPO-R) Signaling as a Novel Approach to Target TET2 Mutation-Driven Clonal Hematopoiesis

Role of Thrombopoietin Receptor (TPO-R) Signaling in TET2 Mutation-Driven Clonal Hematopoiesis

Repurposing Metformin to Target TET2 Mutation Driven Clonal Hematopoiesis and Malignant Transformation

PINK1 Inhibition as a Novel Therapeutic Strategy to Target Acute Myeloid Leukemia Stem Cells

Frequent collaborators

Aaron Schimmer

Tracy Stockley

Mark Minden

Jonas Mattsson

Rajat Kumar

Mohammad Kohandel

Ahmed Aman

Adam Smith

Zhaolei Zhang

Mathieu Lupien

Wei Xu